The FDA has updated its MAPP for staff, revising the “Understanding CDER’s Risk-Based Site Selection Model” (5014.1 Rev. 1). The update details how the FDA will prioritize inspections under the SSM and adds a risk factor for establishments in countries with a history of violations. This is a new risk factor for a region or entire country, whereas previously, mainly individual criteria such as site quality history, site type, and time since last inspection were used.
This is a fascinating addition, and I’d love to see the actual data on this risk factor. Anyone know if this can be FOIA’d? It would be interesting to see the difference between India and Mexico or even if they’ve subdivided the US.
